Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Capecitabine (Primary) ; CB 839 (Primary)
- Indications Colon cancer; Colorectal cancer; Rectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2018 Planned End Date changed from 1 Jan 2020 to 1 Jul 2020.
- 29 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.
- 09 Sep 2016 Planned number of patients changed from 47 to 53.